NEW YORK--(BUSINESS WIRE)--Attorney Advertising-Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Verrica Pharmaceuticals Inc. (“Verrica” or the “Company”) (NASDAQ: VRCA) and certain of its officers, on behalf of all persons and entities that purchased, or otherwise acquired Verrica securities between May 28, 2021 and May 24, 2022, inclusive (the “Class Period”). Such investors are encouraged to join this case by visiting the firm’s site: www.bgandg.com/vrca.
This class action seeks to recover damages against Defendants for alleged violations of the federal securities laws.
The Complaint alleges that throughout the Class Period, Defendants made materially false and/or misleading, and failed to disclose material adverse facts about the Company's business, operations, and prospects. Specifically, Defendants failed to disclose to investors: (1) that there were manufacturing deficiencies at the facility where the Company's contract manufacturer produced bulk solution for VP-102; (2) that these deficiencies were not remediated when the Company resubmitted its NDA for VP-12 for molluscum; (3) that the foregoing presented significant risks to the Company obtaining regulatory approval of VP-102 for molluscum; and (4) that, as a result of the foregoing, Defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis.
A class action lawsuit has already been filed. If you wish to review a copy of the Complaint you can visit the firm’s site: www.bgandg.com/vrca or you may contact Peretz Bronstein, Esq. or his Law Clerk and Client Relations Manager, Yael Nathanson of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484. If you suffered a loss in Verrica you have until August 5, 2022 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.
Bronstein, Gewirtz & Grossman, LLC represents investors in securities fraud class actions and shareholder derivative suits. The firm has recovered hundreds of millions of dollars for investors nationwide. Attorney advertising. Prior results do not guarantee similar outcomes.